Log in

NASDAQ:CLSNCelsion News Headlines

$2.78
-0.08 (-2.80 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.76
Now: $2.78
$2.93
50-Day Range
$1.12
MA: $1.75
$3.03
52-Week Range
$0.69
Now: $2.78
$3.65
Volume678,904 shs
Average Volume3.00 million shs
Market Capitalization$81.34 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45

Headlines

Celsion (NASDAQ CLSN) News Headlines

Source:
DateHeadline
Critical Survey: Akcea Therapeutics (NASDAQ:AKCA) and Celsion (NASDAQ:CLSN)Critical Survey: Akcea Therapeutics (NASDAQ:AKCA) and Celsion (NASDAQ:CLSN)
www.americanbankingnews.com - June 4 at 11:38 AM
Celsion jumps 12% after getting DSMB go-ahead for OVATION Phase 2Celsion jumps 12% after getting DSMB go-ahead for OVATION Phase 2
seekingalpha.com - May 30 at 1:37 PM
Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian CancerCelsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer
finance.yahoo.com - May 29 at 2:10 PM
Celsion (CLSN) Announces Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer - StreetInsider.comCelsion (CLSN) Announces Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer - StreetInsider.com
www.streetinsider.com - May 29 at 9:09 AM
Celsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer - GlobeNewswireCelsion Reports Data Safety Monitoring Board Recommendation to Proceed to Phase II of the OVATION 2 Study in Advanced Ovarian Cancer - GlobeNewswire
www.globenewswire.com - May 29 at 9:09 AM
30 Stocks Moving in Fridays Pre-Market Session - Benzinga30 Stocks Moving in Friday's Pre-Market Session - Benzinga
www.benzinga.com - May 22 at 8:33 AM
Celsion and Altimmune among healthcare gainers; Aurora Cannabis among losers - Seeking AlphaCelsion and Altimmune among healthcare gainers; Aurora Cannabis among losers - Seeking Alpha
seekingalpha.com - May 20 at 1:04 PM
Celsion: Big Gains Possible In July - Seeking AlphaCelsion: Big Gains Possible In July - Seeking Alpha
seekingalpha.com - May 20 at 1:37 AM
Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2020 Results - Earnings Call Transcript - Seeking AlphaCelsion Corporation (CLSN) CEO Michael Tardugno on Q1 2020 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 15 at 10:42 PM
BRIEF-Celsion Reports Q1 Loss Per Share Of $0.20 - ReutersBRIEF-Celsion Reports Q1 Loss Per Share Of $0.20 - Reuters
www.reuters.com - May 15 at 12:40 PM
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update - GlobeNewswireCelsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update - GlobeNewswire
www.globenewswire.com - May 15 at 12:40 PM
Celsion Corporation Reports First Quarter 2020 Financial Results and Provides Business UpdateCelsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - May 15 at 12:40 PM
AMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues - Yahoo FinanceAMAG Pharmaceuticals (AMAG) Reports Q1 Loss, Beats on Revenues - Yahoo Finance
finance.yahoo.com - May 12 at 6:02 PM
Axsomes (AXSM) Earnings Miss in Q1, Pipeline Progresses - Yahoo FinanceAxsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses - Yahoo Finance
finance.yahoo.com - May 11 at 4:15 PM
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020
finance.yahoo.com - May 8 at 8:15 PM
Celsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020 - GlobeNewswireCelsion Corporation to Hold First Quarter 2020 Financial Results Conference Call on Friday, May 15, 2020 - GlobeNewswire
www.globenewswire.com - May 8 at 9:44 AM
Celsion nets $2.5M from sale of NOLs - Seeking AlphaCelsion nets $2.5M from sale of NOLs - Seeking Alpha
seekingalpha.com - April 23 at 3:38 PM
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program - GlobeNewswireCelsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program - GlobeNewswire
www.globenewswire.com - April 23 at 10:34 AM
Celsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection ProgramCelsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program
finance.yahoo.com - April 23 at 10:34 AM
Global Nucleic Acid Based Gene Therapy Industry to 2030 - Featuring Celsion Corporation, Wave Life Sciences & Imugene Among Others - GlobeNewswireGlobal Nucleic Acid Based Gene Therapy Industry to 2030 - Featuring Celsion Corporation, Wave Life Sciences & Imugene Among Others - GlobeNewswire
www.globenewswire.com - April 17 at 3:49 PM
If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, Youd Be Sitting On A 97% Loss, Today - Yahoo FinanceIf You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 97% Loss, Today - Yahoo Finance
finance.yahoo.com - April 17 at 3:49 PM
If You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 97% Loss, TodayIf You Had Bought Celsion (NASDAQ:CLSN) Stock Five Years Ago, You'd Be Sitting On A 97% Loss, Today
finance.yahoo.com - April 17 at 3:49 PM
BRIEF-Celsion Reports That Sufficient Events Have Been Reached For Second Interim Analysis Of Phase III Optima Study Of Thermodox In Primary Liver Cancer - ReutersBRIEF-Celsion Reports That Sufficient Events Have Been Reached For Second Interim Analysis Of Phase III Optima Study Of Thermodox In Primary Liver Cancer - Reuters
www.reuters.com - April 15 at 1:09 PM
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer - GlobeNewswireCelsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer - GlobeNewswire
www.globenewswire.com - April 15 at 1:09 PM
Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver CancerCelsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
finance.yahoo.com - April 15 at 1:09 PM
Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMT - Yahoo FinanceEdited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMT - Yahoo Finance
finance.yahoo.com - March 27 at 2:12 PM
Celsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm - Yahoo FinanceCelsion’s OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm - Yahoo Finance
finance.yahoo.com - March 27 at 2:12 PM
Edited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMTEdited Transcript of CLSN earnings conference call or presentation 26-Mar-20 3:00pm GMT
finance.yahoo.com - March 27 at 9:04 AM
Celsion Corporations (CLSN) CEO Michael Tardugno on Q4 2019 Results - Earnings Call Transcript - Seeking AlphaCelsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 26 at 5:49 PM
Celsions OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm - GlobeNewswireCelsion's OVATION 1 Study with GEN-1 in Ovarian Cancer Shows Strong Progression-Free Survival Treatment Effect Utilizing Medidata Synthetic Control Arm - GlobeNewswire
www.globenewswire.com - March 26 at 12:48 PM
Celsion Corporation Reports 2019 Financial Results and Provides Business Update - GlobeNewswireCelsion Corporation Reports 2019 Financial Results and Provides Business Update - GlobeNewswire
www.globenewswire.com - March 25 at 11:41 PM
Celsion Corporation (CLSN)Celsion Corporation (CLSN)
uk.finance.yahoo.com - March 25 at 6:41 PM
Celsion EPS beats by $0.17, misses on revenueCelsion EPS beats by $0.17, misses on revenue
seekingalpha.com - March 25 at 6:41 PM
Celsion Corporation Reports 2019 Financial Results and Provides Business UpdateCelsion Corporation Reports 2019 Financial Results and Provides Business Update
finance.yahoo.com - March 25 at 6:40 PM
BRIEF-Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation From The European Medicines Agency - ReutersBRIEF-Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation From The European Medicines Agency - Reuters
www.reuters.com - March 23 at 2:06 PM
Celsion (CLSN) Reports GEN-1 Immunotherapy Granted Orphan Drug Designation from European Medicines Agency - StreetInsider.comCelsion (CLSN) Reports GEN-1 Immunotherapy Granted Orphan Drug Designation from European Medicines Agency - StreetInsider.com
www.streetinsider.com - March 23 at 9:06 AM
Celsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency - Yahoo FinanceCelsion’s GEN-1 Immunotherapy Receives Orphan Drug Designation from the European Medicines Agency - Yahoo Finance
finance.yahoo.com - March 23 at 9:06 AM
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020 - GlobeNewswireCelsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020 - GlobeNewswire
www.globenewswire.com - March 20 at 6:07 PM
BRIEF-Celsion Announces Highly Encouraging Initial Clinical Results From The Phase I Portion Of The Phase I/II Ovation 2 Study With Gen-1 In Patients With Advanced Ovarian Cancer - ReutersBRIEF-Celsion Announces Highly Encouraging Initial Clinical Results From The Phase I Portion Of The Phase I/II Ovation 2 Study With Gen-1 In Patients With Advanced Ovarian Cancer - Reuters
www.reuters.com - March 19 at 8:05 PM
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020 - Yahoo FinanceCelsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020 - Yahoo Finance
finance.yahoo.com - March 19 at 8:05 PM
Celsion up 13% premarket on encouraging GEN-1 dataCelsion up 13% premarket on encouraging GEN-1 data
seekingalpha.com - March 19 at 3:05 PM
Celsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian CancerCelsion Announces Highly Encouraging Initial Clinical Results from the Phase I Portion of the Phase I/II OVATION 2 Study with GEN-1 in Patients with Advanced Ovarian Cancer
finance.yahoo.com - March 19 at 3:05 PM
Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020Celsion Corporation to Hold Year-End 2019 Financial Results Conference Call on Thursday, March 26, 2020
finance.yahoo.com - March 19 at 3:05 PM
Form SC 13G Celsion CORP Filed by: CVI Investments, Inc. - StreetInsider.comForm SC 13G Celsion CORP Filed by: CVI Investments, Inc. - StreetInsider.com
www.streetinsider.com - March 6 at 1:37 PM
Celsion CEO Issues Letter to Stockholders Nasdaq:CLSN - GlobeNewswireCelsion CEO Issues Letter to Stockholders Nasdaq:CLSN - GlobeNewswire
www.globenewswire.com - March 4 at 5:40 PM
Celsion CEO Issues Letter to Stockholders - StreetInsider.comCelsion CEO Issues Letter to Stockholders - StreetInsider.com
www.streetinsider.com - March 4 at 7:40 AM
Celsion CEO Issues Letter to Stockholders - Yahoo FinanceCelsion CEO Issues Letter to Stockholders - Yahoo Finance
finance.yahoo.com - March 3 at 3:10 PM
Celsion CEO Issues Letter to StockholdersCelsion CEO Issues Letter to Stockholders
finance.yahoo.com - March 3 at 3:10 PM
Celsion Corporation Prices $4.8 Million Registered Direct Offering - GlobeNewswireCelsion Corporation Prices $4.8 Million Registered Direct Offering - GlobeNewswire
www.globenewswire.com - February 29 at 1:51 PM
Brazil real hits new low despite FX intervention, now down 11% this year - NasdaqBrazil real hits new low despite FX intervention, now down 11% this year - Nasdaq
www.nasdaq.com - February 28 at 11:38 PM
This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.